Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

$24.99

Income Statement
Quarterly Data

The income statement presents information on the financial results of a company business activities over a period of time. The income statement communicates how much revenue the company generated during a period and what cost it incurred in connection with generating that revenue.

Paying user area

Try for free

Gilead Sciences Inc. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Gilead Sciences Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Product sales
Cost of goods sold
Gross profit on product sales
Royalty, contract and other revenues
Research and development expenses
Acquired in-process research and development expenses
In-process research and development impairments
Selling, general and administrative expenses
Operating income (loss)
Interest expense
Other income (expense), net
Income (loss) before income taxes
Income tax (expense) benefit
Net income (loss)
Net loss attributable to noncontrolling interest
Net income (loss) attributable to Gilead

Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).

Revenue trajectories demonstrate a general upward trend over the observed period, with product sales increasing from approximately 6.3 billion US dollars in early 2021 to a peak of 7.9 billion US dollars by the end of 2025. While quarterly fluctuations occur, the top-line growth is characterized by a steady climb in sales volume, particularly evident in the 2024 and 2025 fiscal years.

Gross Profitability and Margin Stability
Gross profit on product sales generally tracks with revenue growth, maintaining a high margin profile. Most quarters see gross profits ranging between 4.5 billion and 6.3 billion US dollars. The cost of goods sold remains relatively stable, typically fluctuating between 1.3 billion and 1.6 billion US dollars, though a notable spike occurred in December 2021, which temporarily compressed gross margins.
Operating Expenditure Patterns
Research and development (R&D) expenses show a consistent commitment to innovation, with spending typically ranging from 1.1 billion to 1.6 billion US dollars per quarter. Selling, general, and administrative (SG&A) expenses exhibit more volatility, frequently spiking toward 2.0 billion US dollars in year-end quarters, suggesting seasonal adjustments or period-end administrative costs.
Non-Recurring Financial Impacts
The most significant volatility in operating income is driven by acquired in-process research and development (IPRD) expenses and IPRD impairments. Substantial one-time charges are observed in March 2024 (4.1 billion US dollars) and June 2026 (11.2 billion US dollars). These events, combined with periodic impairments such as the 2.7 billion US dollar charge in March 2022, create deep periodic deficits in operating income despite strong core product sales.
Net Income and Bottom-Line Performance
Net income is characterized by strong positive returns in standard operational quarters, often exceeding 1.5 billion US dollars. However, the bottom line is heavily distorted by the aforementioned IPRD charges. This results in extreme swings, such as the net loss of 4.17 billion US dollars in March 2024 and a net loss of 10.5 billion US dollars in June 2026, reflecting a strategic investment or write-down cycle rather than a decline in operational efficiency.

In summary, the core operational performance remains robust with growing product sales and stable gross margins. The financial profile is defined by a dichotomy between steady organic growth and significant, irregular losses stemming from strategic acquisitions and asset impairments.